J&J Settles Talc Cancer Claims for $5.5 Billion

Johnson and Johnson announced on Monday a proposed settlement of roughly 5.5 billion dollars to resolve the bulk of remaining lawsuits claiming its talc based baby powder and similar products caused ovarian cancer. The agreement covers about 76,000 claims consolidated in federal court in New Jersey along with parallel state cases, marking the latest step in more than a decade of litigation over products the company once marketed for feminine hygiene use.

The deal requires approval from law firms representing at least 95 percent of the claimants before it becomes final. Johnson and Johnson expects to pay 3 billion dollars in 2027 with additional installments scheduled for 2028, though the total could rise depending on participation rates. Plaintiffs lawyers involved in negotiations, including Chris Seeger who represents about 2,500 clients, have suggested the figure could ultimately reach 7 billion dollars or higher once all qualifying claims are valued.

The company has long maintained that the claims lack merit and that its talc products do not contain asbestos or cause cancer. Erik Haas, vice president of litigation, said the resolution allows Johnson and Johnson to move past the matter and concentrate on developing medicines and devices. The firm previously prevailed in most cases that reached trial, yet it chose to settle to achieve finality after years of appeals and new filings.

Separate earlier settlements addressed the majority of mesothelioma claims tied to alleged asbestos contamination in the talc. The current agreement focuses specifically on ovarian cancer allegations, which plaintiffs have supported with references to epidemiological studies dating back to the 1980s that examined links between genital talc use and increased cancer risk. Johnson and Johnson has countered those findings with its own scientific reviews and regulatory positions that found insufficient evidence of causation.

The scale of the litigation reflects persistent questions about how consumer product safety information reaches the public and how companies respond when scientific associations emerge. Courts have seen waves of cases since the late 2000s, with Johnson and Johnson already paying out billions in prior judgments and resolutions. The new settlement consolidates nearly all outstanding ovarian cancer claims into a single framework, reducing the prospect of further scattered trials that could produce conflicting results.

Plaintiffs firms described the outcome as a pragmatic end to prolonged proceedings, while the company framed it as a strategic choice rather than an admission of liability. The structure of payments spread over multiple years also illustrates how large corporations manage the financial impact of mass tort resolutions without immediate disruption to operations. As the agreement moves toward the required participation threshold, attention will turn to how the claims are valued and whether the process provides consistent outcomes for women who used the products over decades.